Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has raised questions about the efficacy and data of Capricor Therapeutics' drug intended to treat Duchenne heart disease. These concerns were raised ahead of a scheduled hearing.
Coverage from Reuters, STAT, and WTVB emphasizes the FDA staff's flags regarding the therapy, while Reuters notes a subsequent plunge in company shares. Yahoo Finance and MarketBeat report on the stock's current trading status, including a lease deal and a high volume of call options purchased by traders.
Attention now turns to the upcoming hearing to address the FDA's concerns. Coverage does not yet specify the date of the hearing or the exact nature of the data discrepancies.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What did the FDA flag regarding Capricor's therapy?
FDA staff flagged concerns regarding the efficacy and data of the Duchenne heart disease therapy.
How did the market react to the FDA news?
According to Reuters, shares of Capricor Therapeutics plunged following the reports.
What other market activity is noted for CAPR?
MarketBeat reports that stock traders have purchased a large volume of call options on the company.
Coverage (6)
- Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel simplywall.st · 3h ago
- FDA staff flags concerns for Capricor’s Duchenne heart disease therapy WTVB · 3h ago
- Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) MarketBeat · 3h ago
- FDA staff flags data concerns about Capricor's therapy; shares plunge Reuters · 3h ago
- Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? Yahoo Finance · 3h ago
- Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug STAT · 3h ago
Topics
Related trends
Compounded GLP-1 drugs creating concern among doctors and FDA
Medical professionals and the FDA are raising alarms over the safety and legality of compounded GLP-1 weight-loss injections.
Cyclospora outbreak has many changing eating habits, CBS News poll finds; mixed and partisan confidence in FDA
A Cyclospora outbreak is shifting consumer eating habits and driving demand for local produce and home-grown greens.
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly has shifted the FDA application timeline for its next-generation obesity drug, retatrutide, to the first quarter of 2027.
Taylor Farms CEO breaks silence over explosive diarrhea outbreak as class-action lawsuit filed
Taylor Farms faces a class-action lawsuit and facility closures amid a rising outbreak of cyclosporiasis.
Brooklyn Roasting Company recalls cold brew sold in New York and New Jersey over botulism risk
Brooklyn Roasting Company is recalling 3,000 gallons of cold brew concentrate due to a botulism risk in New York and New Jersey.
We’re beating heart disease
The FDA has approved enlicitide, the first oral pill designed to replace injections for managing high cholesterol.